Literature DB >> 19852957

Lymphocytic infiltration leads to degradation of lacrimal gland extracellular matrix structures in NOD mice exhibiting a Sjögren's syndrome-like exocrinopathy.

Katja Schenke-Layland1, Jiansong Xie, Mattias Magnusson, Ekaterini Angelis, Xiaodong Li, Kaijin Wu, Dieter P Reinhardt, W Robb Maclellan, Sarah F Hamm-Alvarez.   

Abstract

We previously reported that lacrimal glands (LGs) of male non-obese diabetic (NOD) mice, an established mouse model of autoimmune inflammatory LG disease that displays many features of human LGs in patients afflicted with Sjögren's syndrome (SjS), exhibit significant degradation of extracellular matrix (ECM) structures as well as increased expression of matrix metalloproteinases (MMPs). The purpose of the current study was to expand the spectrum of proteases identified, to clarify their probable origin as well as to identify the contribution of these changes to disease pathogenesis. We explored in depth the changes in ECM structures and ECM protease expression at the onset of disease (6 weeks) versus late stage disease (18 weeks) in male NOD mouse LGs, relative to LGs of age-matched male NODscid, a severely immunocompromised congenic strain, and healthy BALB/c mice. LG tissues were examined using routine histological, immunohistochemical, Western Blot and gene expression analyses novel multiphoton imaging technologies. We further characterized the profile of infiltrating immune cells under each condition using flow cytometry. Our results show that the initial infiltrating cells at 6 weeks of age are responsible for increased MMP and cathepsin H expression and therefore initiate the LG ECM degradation in NOD mice. More importantly, NODscid mice exhibited normal LG ECM structures, indicating the lymphocytes seen in the LGs of NOD mice are responsible for the degradation of the LG ECM. The disease-related remodeling of LG ECM structures may play a crucial role in altering the acinar signaling environment, disrupting the signaling scaffolds within the cells, which are required to mobilize the exocytotic trafficking machinery, ultimately leading to a loss of LG function in patients afflicted with SjS. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19852957      PMCID: PMC2821966          DOI: 10.1016/j.exer.2009.10.008

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  44 in total

1.  Role of laminin-1, collagen IV, and an autocrine factor(s) in regulated secretion by lacrimal acinar cells.

Authors:  L Chen; J D Glass; S C Walton; G W Laurie
Journal:  Am J Physiol       Date:  1998-07

2.  Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjögren's syndrome.

Authors:  S Yamachika; J M Nanni; K H Nguyen; L Garces; J M Lowry; C P Robinson; J Brayer; G E Oxford; A da Silveira; M Kerr; A B Peck; M G Humphreys-Beher
Journal:  J Rheumatol       Date:  1998-12       Impact factor: 4.666

3.  "BM180": a novel basement membrane protein with a role in stimulus-secretion coupling by lacrimal acinar cells.

Authors:  G W Laurie; J D Glass; R A Ogle; C M Stone; J R Sluss; L Chen
Journal:  Am J Physiol       Date:  1996-06

4.  Decreased reflex tearing is associated with lymphocytic infiltration in lacrimal glands.

Authors:  K Tsubota; K P Xu; T Fujihara; S Katagiri; T Takeuchi
Journal:  J Rheumatol       Date:  1996-02       Impact factor: 4.666

5.  Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome.

Authors:  I Matsumoto; K Tsubota; Y Satake; Y Kita; R Matsumura; H Murata; T Namekawa; K Nishioka; I Iwamoto; Y Saitoh; T Sumida
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

6.  Sjögren's syndrome. Proposed criteria for classification.

Authors:  R I Fox; C A Robinson; J G Curd; F Kozin; F V Howell
Journal:  Arthritis Rheum       Date:  1986-05

7.  Lymphocyte phenotype and function in pseudolymphoma associated with Sjögren's syndrome.

Authors:  R I Fox; T C Adamson; S Fong; C A Robinson; E L Morgan; J A Robb; F V Howell
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

8.  Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjögren syndrome.

Authors:  C P Robinson; S Yamachika; C E Alford; C Cooper; E L Pichardo; N Shah; A B Peck; M G Humphreys-Beher
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

9.  Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice.

Authors:  L Kong; C P Robinson; A B Peck; N Vela-Roch; K M Sakata; H Dang; N Talal; M G Humphreys-Beher
Journal:  Clin Exp Rheumatol       Date:  1998 Nov-Dec       Impact factor: 4.473

Review 10.  Matrix metalloproteinases in immunity.

Authors:  E J Goetzl; M J Banda; D Leppert
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

View more
  19 in total

1.  Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice.

Authors:  Jason S Ellis; Xiaoxiao Wan; Helen Braley-Mullen
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

2.  Recapitulation of the embryonic cardiovascular progenitor cell niche.

Authors:  Katja Schenke-Layland; Ali Nsair; Ben Van Handel; Ekaterini Angelis; Jessica M Gluck; Miriam Votteler; Joshua I Goldhaber; Hanna K Mikkola; Michael Kahn; William R Maclellan
Journal:  Biomaterials       Date:  2011-01-22       Impact factor: 12.479

3.  Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse.

Authors:  Xiaodong Li; Kaijin Wu; Maria Edman; Katja Schenke-Layland; Michelle MacVeigh-Aloni; Srikanth Reddy Janga; Barbara Schulz; Sarah F Hamm-Alvarez
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-12       Impact factor: 4.799

4.  A thermo-responsive protein treatment for dry eyes.

Authors:  Wan Wang; Aarti Jashnani; Suhaas R Aluri; Joshua A Gustafson; Pang-Yu Hsueh; Frances Yarber; Robert L McKown; Gordon W Laurie; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2014-12-03       Impact factor: 9.776

5.  Lacrimal Gland Inflammation Deregulates Extracellular Matrix Remodeling and Alters Molecular Signature of Epithelial Stem/Progenitor Cells.

Authors:  Takeshi Umazume; William M Thomas; Sabrina Campbell; Hema Aluri; Suharika Thotakura; Driss Zoukhri; Helen P Makarenkova
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

6.  Role of Matrix Metalloproteinases 2 and 9 in Lacrimal Gland Disease in Animal Models of Sjögren's Syndrome.

Authors:  Hema S Aluri; Claire L Kublin; Suharika Thotakura; Helene Armaos; Mahta Samizadeh; Dillon Hawley; William M Thomas; Paul Leavis; Helen P Makarenkova; Driss Zoukhri
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

7.  NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis.

Authors:  Yaping Ju; Srikanth Reddy Janga; Wannita Klinngam; J Andrew MacKay; Dillon Hawley; Driss Zoukhri; Maria C Edman; Sarah F Hamm-Alvarez
Journal:  Exp Eye Res       Date:  2018-09-08       Impact factor: 3.467

8.  Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.

Authors:  Roy A Fava; Susan M Kennedy; Sheryl G Wood; Anne I Bolstad; Jadwiga Bienkowska; Adrian Papandile; John A Kelly; Clio P Mavragani; Margaret Gatumu; Kathrine Skarstein; Jeffrey L Browning
Journal:  Arthritis Res Ther       Date:  2011-11-01       Impact factor: 5.156

Review 9.  The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man.

Authors:  Naomi I Maria; Petra Vogelsang; Marjan A Versnel
Journal:  Arthritis Res Ther       Date:  2015-07-03       Impact factor: 5.156

10.  Elastogenesis at the onset of human cardiac valve development.

Authors:  Miriam Votteler; Daniel A Carvajal Berrio; Alexander Horke; Laetitia Sabatier; Dieter P Reinhardt; Ali Nsair; Elena Aikawa; Katja Schenke-Layland
Journal:  Development       Date:  2013-05-01       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.